US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by RAPT Therapeutics, Inc.

News headline image
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports First Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers CTNM RAPT
News headline image
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports First Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
News headline image
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT